Mydecine Innovations Group (DB:0NF0) - Cours de l'action, nouvelles et analyse

0NF0 Aperçu des actions

0NF0 analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	0/6
Performances passées	0/6
Santé financière	0/6
Dividendes	0/6

Récompenses

Les revenus ont augmenté 8.7% par an au cours des 5 dernières années

Analyse des risques

Réalise moins d'un million de dollars de revenus ( CA$0 )

N'a pas de capitalisation boursière significative ( €333K )

A moins d'un an de piste de trésorerie

Capitaux propres négatifs

+ 2 plus de risques

Mydecine Innovations Group Inc. Concurrents

Biofrontera

XTRA:B8FK

€15.4m

SynBiotic

DUSE:SBX

€27.9m

MPH Health Care

DB:93M1

€101.9m

Redx Pharma

DB:0RX

€65.0m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Mydecine Innovations Group
Historique des cours de bourse
Prix actuel de l'action	US$0.003
Plus haut sur 52 semaines	US$0.076
Plus bas sur 52 semaines	US$0.0005
Bêta	2.77
1Variation sur 1 mois	0%
Variation sur 3 mois	-80.00%
Variation sur 1 an	-96.00%
3Variation sur 3 ans	-99.95%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-100.00%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	0NF0	DE Pharmaceuticals	DE Marché
7D	0%	1.2%	1.3%
1Y	-96.0%	-19.7%	7.9%

Rendement vs Industrie: 0NF0 a sous-performé le secteur German Pharmaceuticals qui a rapporté -19.7 % au cours de l'année écoulée.

Rendement vs marché: 0NF0 a sous-performé le marché German qui a rapporté 7.9 % au cours de l'année écoulée.

Volatilité des prix

Is 0NF0's price volatile compared to industry and market?
0NF0 volatility
0NF0 Average Weekly Movement	120.2%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: Le cours de l'action de 0NF0 a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de 0NF0 a diminué de 633% à 121% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de German.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2013	3	Josh Bartch	www.mydecine.com

Mydecine Innovations Group Inc. est une société de biotechnologie qui se consacre à la recherche, au développement et à la commercialisation de produits à base de psilocybine pour traiter les problèmes de santé mentale. La société se concentre principalement sur le traitement de la dépendance à la nicotine et du syndrome de stress post-traumatique. Ses principaux produits candidats comprennent MYCO-005.

Mydecine Innovations Group Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Mydecine Innovations Group se comparent-ils à sa capitalisation boursière ?
0NF0 statistiques fondamentales
Capitalisation boursière	€315.14k
Bénéfices(TTM)	-€8.41m
Recettes(TTM)	n/a

0.0x

Ratio P/S

0.0x

Ratio P/E

Le site 0NF0 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
0NF0 compte de résultat (TTM)
Recettes	CA$0
Coût des recettes	CA$0
Marge brute	CA$0
Autres dépenses	CA$12.46m
Les revenus	-CA$12.46m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.20
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	-37.4%

Quelles ont été les performances à long terme de 0NF0?

Voir les performances historiques et les comparaisons

0NF0 Aperçu des actions

Récompenses

Analyse des risques

Mydecine Innovations Group Inc. Concurrents

XTRA:B8FK

€15.4m

DUSE:SBX

€27.9m

DB:93M1

€101.9m

DB:0RX

€65.0m

Historique des prix et performances

Nouvelles et mises à jour récentes

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Recent updates

New major risk - Financial position

New minor risk - Financial data availability

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials